Longview Acquisition Corp. II
LGV
New York Stock Exchange10.09
USD
- -
- -
Longview Acquisition Corp. II
LGV
(New York Stock Exchange)
Recent
price
10.09
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Longview Acquisition Corp. II (NYSE: LGV) is a blank check company with no significant operations whose principal purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses; it targets opportunities principally in the healthcare, industrials, consumer, media, technology, and technology services sectors. The company offers no current products or services beyond its SPAC structure, including redeemable units comprising Class A ordinary shares and public warrants exercisable for additional shares; it maintains its trust account assets primarily in U.S. Treasury securities and money market funds. Incorporated in 2020 and headquartered at 767 Fifth Avenue, New York, New York, Longview Acquisition operates principally in the United States with a global target geography for potential business combinations. In December 2022, Longview Acquisition amended its charter and trust agreement to extend its business combination deadline to December 14, 2022, following which stockholders redeemed approximately 60.9 million public shares for $613 million, leaving about 8.1 million shares outstanding; the company subsequently announced its intent to redeem all remaining public shares, delist from the NYSE, and fully liquidate due to failure to complete a merger within the amended timeframe. Previously, in July 2021, it entered a $2.4 billion business combination agreement with HeartFlow Holding Inc., a precision heart care company, which mutually terminated in February 2022; no subsequent mergers, acquisitions, funding rounds, or strategic shifts have been completed as of late 2025, with the entity marked as inactive or potentially delisted amid zero ongoing operations or revenue. Current stock pricing around $10.09 reflects residual trust distributions, with no active business segments or subsidiaries.
HeartFlow, Longview Acquisition SPAC Deal Called Off
Heartflow Charts NYSE Debut IPO Via $2.4B SPAC Deal